NASDAQ:ALLK - Allakos Stock Price, Forecast & News

Allakos trades on the NASDAQ under the ticker symbol "ALLK."

Allakos Inc (NASDAQ:ALLK) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.47) earnings per share for the quarter, missing analysts' consensus estimates of ($0.43) by $0.04. View Allakos' Earnings History.

Allakos is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Allakos.

2 Wall Street analysts have issued 12 month target prices for Allakos' shares. Their forecasts range from $94.00 to $94.00. On average, they expect Allakos' share price to reach $94.00 in the next twelve months. This suggests a possible upside of 43.2% from the stock's current price. View Analyst Price Targets for Allakos.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Allakos.

News headlines about ALLK stock have trended very negative on Saturday, InfoTrie reports. The research group rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Allakos earned a daily sentiment score of -3.5 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Allakos.

Allakos saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 7,400,000 shares, an increase of 6.5% from the January 15th total of 6,950,000 shares. Based on an average daily trading volume, of 430,100 shares, the short-interest ratio is presently 17.2 days. Approximately 33.0% of the shares of the stock are sold short. View Allakos' Current Options Chain.

Some companies that are related to Allakos include Elanco Animal Health (ELAN), Mylan (MYL), Beigene (BGNE), Ono Pharmaceutical (OPHLF), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Catalent (CTLT), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Ascendis Pharma A/S (ASND), Reata Pharmaceuticals (RETA) and The Medicines (MDCO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include Eiger Biopharmaceuticals (EIGR), Gilead Sciences (GILD), Heron Therapeutics (HRTX), AbbVie (ABBV), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Advanced Micro Devices (AMD), BioTelemetry (BEAT), bluebird bio (BLUE) and Global Blood Therapeutics (GBT).

(ALLK) raised $96 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 6,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and William Blair was co-manager.

Allakos' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Capital Research Global Investors (11.07%), Capital World Investors (8.36%), Capital International Investors (8.22%), FMR LLC (2.91%), State Street Corp (1.66%) and Geode Capital Management LLC (0.68%). Company insiders that own Allakos stock include Daniel Janney, John P Mckearn and Venture Fund (Ohi Rivervest II. View Institutional Ownership Trends for Allakos.

ALLK stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Victory Capital Management Inc., Victory Capital Management Inc., Renaissance Technologies LLC, Driehaus Capital Management LLC, Samsara BioCapital LLC, UBS Group AG and Rafferty Asset Management LLC. Company insiders that have sold Allakos company stock in the last year include John P Mckearn and Venture Fund (Ohi Rivervest II. View Insider Buying and Selling for Allakos.

ALLK stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, Capital World Investors, Capital Research Global Investors, Pictet Asset Management Ltd., Capital International Inc. CA, Fairmount Funds Management LLC, Handelsbanken Fonder AB and Candriam Luxembourg S.C.A.. Company insiders that have bought Allakos stock in the last two years include Daniel Janney and Venture Fund (Ohi Rivervest II. View Insider Buying and Selling for Allakos.

Shares of ALLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ALLK stock can currently be purchased for approximately $65.62.

Allakos has a market capitalization of $3.19 billion. The company earns $-43,540,000.00 in net income (profit) each year or ($2.20) on an earnings per share basis. Allakos employs 62 workers across the globe.View Additional Information About Allakos.

The official website for Allakos is http://www.allakos.com/.

Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-597-5002 or via email at [email protected]